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Abstract
Background: Anticoagulant therapy for venous thromboembolism (VTE) in children 
is largely based on treatment recommendations for adults. However, differences in 
both physiology (ie, renal maturation and drug excretion) and developmental hemo-
stasis must be considered when treating children, as such differences could affect 
dose appropriateness, safety and efficacy.
Objectives: To address these concerns, a study was designed to evaluate the safety 
of dabigatran etexilate in children requiring secondary thrombus prevention in whom 
an initial VTE was associated with an identified risk factor that persisted after the 
acute VTE treatment period. We report herein the rationale and design of the study.
Patients/Methods: This phase 3, open- label, single- arm, multicenter, multinational, 
prospective cohort study will be conducted in ≥100 children aged 0 to <18 years at 
     |  581LUCIANI et AL.
1  | INTRODUCTION
Venous thromboembolism (VTE) in children is typically secondary to 
underlying diseases and/or their treatment, or to acquired thrombo-
sis risk factors.1 In pediatric patients, VTE has an annual incidence 
of approximately 0.07- 0.14 events per 10 000 children,2 but the 
number of cases appears to be rising.3 Raffini et al. reported a 70% 
increase in VTE cases among neonates, infants, children, and adoles-
cents in tertiary pediatric institutions in the United States between 
2001 and 2007.4 The increased incidence could be due to a height-
ened level of awareness towards pediatric VTE among healthcare 
professionals, better diagnostic techniques leading to more frequent 
identification, improved survival of children with more complex or 
catastrophic conditions, and more frequent use of interventions 
such as central venous catheters, which is the most common risk 
factor for pediatric VTE.4
The current standard of care for pediatric patients with acute 
VTE is anticoagulant treatment with unfractionated heparin or 
low- molecular- weight heparin (LMWH) followed by several weeks 
or months of treatment with LMWH, or oral vitamin K antagonists 
(VKAs).1,5 Estimates of the rate of pediatric VTE recurrence vary 
widely,6,7 ranging between 2% and 21%.8 Post- thrombotic syn-
drome (PTS), another long- term consequence of VTE, has been 
reported in 12- 65% of children following an initial VTE.1,7,9–12 Risk 
factors associated with VTE recurrence include underlying chronic 
conditions associated with a prothrombotic tendency, such as ma-
lignancies, cardiac/vascular abnormalities, short bowel syndrome 
with total parenteral nutrition dependency, or congenital disorders 
(eg, severe inherited thrombophilias). In addition, chronic con-
ditions with interim disease flares such as in inflammatory disor-
ders (eg, systemic lupus erythematosus, bowel disorders, systemic 
sclerosis, or vasculopathies), infections (eg, infective endocarditis 
or bone infections), and nephrotic syndrome can be accompanied 
by intermittent prothrombotic periods. Lastly, acquired risk fac-
tors are typically exemplified by the presence of central venous 
catheters.1,2,4,6,8,13–15
When a risk factor is present, anticoagulant therapy, usually 
with LMWH or oral VKAs, may be extended beyond the acute pe-
riod to prevent VTE recurrence until the risk factor has resolved, or 
be administered lifelong in selected cases.1 While both treatments 
yield acceptable clinical results, their use in pediatric VTE presents 
challenges.1 For instance, parenteral administration of LMWH, the 
need for regular monitoring of the international normalized ratio 
(INR) with VKAs, as well as risks due to VKA- related food–drug and 
drug–drug interactions, may represent a burden to children and their 
families, directly affecting treatment feasibility and compliance, and 
ultimately, efficacy. There is an unmet need for therapies that can 
overcome these challenges.14
The efficacy and safety of dabigatran etexilate have been demon-
strated in a number of indications in adults. These include the acute 
~100 specialist sites worldwide. Children will be treated with dabigatran etexilate for 
12 months, or for a shorter duration if their identified VTE risk factor resolves, as per 
current American College of Chest Physicians recommendations. A nomogram will be 
used to determine starting doses for each patient.
Results: The primary outcomes of the study will be VTE recurrence, bleeding events, 
overall mortality, and VTE- related mortality. Secondary outcomes will include occur-
rence of post- thrombotic syndrome, the pharmacokinetics of dabigatran, and the 
need for dose adjustments during treatment. Data on adverse events during the 
study will also be collected.
Conclusion: This study will evaluate the safety of dabigatran etexilate for the second-
ary prevention of VTE in children, in addition to providing further data to guide pedi-
atric dosing with dabigatran.
K E Y W O R D S
anticoagulant, dabigatran, pediatrics, secondary prevention, venous thromboembolism
Essentials
• Treating pediatric venous thromboembolism (VTE) based upon adult guidelines may be inappropriate.
• This phase 3 trial will assess the safety of dabigatran for secondary VTE prevention in children.
• A dosing algorithm will be used to determine individualized dabigatran doses.
• The study will provide key data on dabigatran safety and guide pediatric dosing recommendations.
582  |     LUCIANI et AL.
treatment of VTE,16–18 the acute treatment of VTE in the presence 
of cancer,19 and extended treatment for secondary prevention of 
VTE,20 for which dabigatran etexilate was shown to be non- inferior 
to well- controlled warfarin, with an overall reduced risk of bleeding, 
and superior in efficacy compared with placebo.
Anticoagulant therapy for pediatric VTE is based mostly 
on extrapolations from recommendations for the treatment of 
adults.1,14,21 There are, however, important differences between 
adults and children that must be considered. For example, unpro-
voked VTE is rarer in the pediatric population6,22: in children, up to 
95% of VTEs are secondary to an identifiable risk factor,1 whereas 
there is no readily identifiable risk factor in approximately 25- 50% 
of adults with VTE.23 The continued presence of a risk factor in pe-
diatric patients is therefore an important consideration when mak-
ing decisions about continued anticoagulation. Adults and children 
also have differences in their coagulation systems, the maturation of 
which is not complete until adolescence. Developmental differences 
in coagulation maturation are exemplified by lower circulating levels 
of both procoagulant and natural anticoagulant proteins in children 
versus adults,24,25 particularly in infants,26 which may affect the way 
children respond to anticoagulant drugs. In the case of dabigatran, 
which is primarily renally excreted,27,28 differences in maturation of 
renal function are considered important in determining safe and ef-
fective pediatric dosages.29 Guidance from the US Food and Drug 
Administration (FDA) notes that if the course of a disease and the ef-
fects of a particular drug treatment are similar in adults and children, 
findings on drug effectiveness might be extrapolated from adults 
to children.30 This same FDA guidance and corresponding guidance 
from the European Medicines Agency, however, states that extrapo-
lation of findings on drug safety from adults to pediatric populations 
is not appropriate.30,31
Findings from studies of dabigatran etexilate in children have 
been promising (Table 1). In an in vitro study, fibrin clot generation 
and lysis assay responses to dabigatran in children aged 0 to <18 
years were consistent and comparable with those of adults.32 A 
three- day, phase 2a, open- label study in adolescent patients who 
had successfully completed planned treatment for VTE showed 
similar pharmacokinetic (PK)/pharmacodynamic (PD) relationships 
in children and adults; dabigatran was also generally well toler-
ated.33 The PK and PD of dabigatran administered as oral liquid 
formulation were evaluated in 2 phase 2a, open- label, safety and 
tolerability studies in pediatric patients with VTE. One study in-
cluded patients aged 1 to <2 years and the other study included 
patients aged <1 year. In both studies, the projected steady- state 
trough concentrations of dabigatran were largely comparable 
with those in adults with VTE. A linear relationship was observed 
between PK and PD for diluted thrombin time (dTT) and ecarin 
clotting time, and a non-linear relationship was observed between 
PK and PD for activated partial thromboplastin time. These PK/
PD findings are largely comparable with those observed in adults 
with VTE. There were no bleeding events or other adverse events 
(AEs) during the studies.34,35 Furthermore, dabigatran etexilate is 
also being compared with LMWH or oral VKAs for the treatment 
of acute VTE in an open- label, randomized, active- controlled, 




In vitro 41 To determine the optimum coagulation assays for 
dabigatran in children and the anticoagulant effect 
of dabigatran across pediatric age groups
● Diluted thrombin time was the most suitable assay for 
indirect assessment of dabigatran concentrations in 
children
● Fibrin clot generation and lysis assay responses to 
dabigatran across the pediatric age range were 
consistent with and comparable to those in adults
2a 9 To investigate the tolerability and safety of 
dabigatran etexilate in adolescents who had 
completed either LMWH or oral anticoagulation for 
primary VTE, and to explore PK and PD in this age 
group
● Dabigatran etexilate was generally well tolerated
● The dabigatran PK/PD relationship in adolescent 
patients was similar to that in adults
2a 18 To examine the PK and PD of an oral liquid 
formulation of dabigatran etexilate and to evaluate 
its tolerability and safety in patients ages 1 to 
<12 years
● The oral liquid formulation was well tolerated
● Projected steady-state dabigatran trough concentra-
tions were largely comparable with those in adults with 
VTE
● The PK/PD relationship in this age group was similar to 
that seen in adults and adolescents with VTE
2a 8 To examine the PK and PD of an oral liquid 
formulation of dabigatran etexilate and to evaluate 
its tolerability and safety in patients aged <1 year
● The oral liquid formulation was well tolerated
● Projected steady-state dabigatran trough concentra-
tions were largely comparable with those in adults with 
VTE
● The PK/PD relationship in this age group was similar to 
that seen in adults and adolescents with VTE
LMWH, low- molecular- weight heparin; PD, pharmacodynamics; PK, pharmacokinetic; VTE, venous thromboembolism.
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multicenter, phase 3 study in children aged 0 to <18 years 
(NCT01895777).
2  | OBJECTIVES
The aim of this study is to provide information regarding the safety 
(with efficacy criteria considered safety- related) of extended anti-
coagulant therapy with dabigatran etexilate when used for the sec-
ondary prevention of VTE in children aged 0 to <18 years. Primary 
outcomes include VTE recurrence, bleeding events, and mortality. 
Secondary outcomes include PTS, the PK and PD of dabigatran 
etexilate, and the number of patients who require a dose adjustment 
during treatment. Findings from the study will complement those 
from NCT01895777, which is to assess dabigatran in the acute VTE 
setting.
3  | METHODS
3.1 | Study design and timeline
This is a phase 3, open- label, single- arm, multicenter, multinational, 
prospective cohort study that will include ≥100 patients. The study 
will be conducted worldwide at approximately 100 trial sites, most 
of which will be specialized referral centers experienced in the man-
agement of pediatric VTE. Patients will be treated with dabigatran 
etexilate for up to 12 months, or less if the identified clinical risk 
factor for VTE resolves. A post- treatment follow- up visit will be con-
ducted 28 days after the last intake of the study drug. A timeline for 
the study with details of study visits and assessments is shown in 
Table 2. Patients who stop treatment before 12 months, either as a 
result of VTE risk factor resolution or early treatment discontinua-
tion, will be invited for an end- of- treatment visit and then followed 
according to the remainder of the visit schedule. At the end of their 
participation in the study, all patients will discontinue dabigatran 
etexilate; if there is an ongoing risk factor, they will be required to 
switch to standard of care. The end of the trial will be defined as the 
date of completion of the last study visit by the last patient.
3.2 | Oversight
Figure 1 outlines the administrative and oversight structure of the 
trial. A steering committee comprising academic and sponsor mem-
bers will provide scientific leadership and has final responsibility 
for the trial design, the development of the protocol and the con-
duct and oversight of the study. The study sponsor is Boehringer 
Ingelheim (Ingelheim, Germany). The study protocol will be sub-
mitted for approval by the national competent authority and the 
institutional review board or ethics committee for each partici-
pating center. Written informed consent, and assent if applicable, 
will be obtained before study commencement from the patient’s 
parent(s) or legal guardian, and/or the patient, in accordance with 
local legislation.
An independent data monitoring committee (DMC) will review 
safety on an ongoing basis and will advise the sponsor on continu-
ation, modification, or termination of the study, according to a de-
tailed DMC charter. The DMC will also review the study results and 
monitor the overall dabigatran etexilate pediatric study program. An 
independent adjudication committee will evaluate all primary out-
come events. All laboratory samples for the planned safety assess-
ments will be analyzed centrally, although local laboratories may be 
employed if needed and when feasible to evaluate some assays, such 
as dTT, for the evaluation of dabigatran anticoagulant activity and 
corresponding plasma levels, INR, serum creatinine, and hemoglo-
bin. Samples for PK and PD evaluations will be analyzed at contract 
research organization laboratories.
3.3 | Patients
Participants will be males and females aged <18 years who require 
anticoagulant therapy for secondary prevention of VTE because 
of the presence of an ongoing clinical risk factor for VTE recur-
rence (Table 3). The VTE risk factor must be specified for each 
patient during pretrial screening and will then be reevaluated at 
each visit to determine the need for continuing treatment. The key 
inclusion and exclusion criteria for study participants are summa-
rized in Table 3. Eligible patients must have completed at least 3 
months of initial anticoagulant treatment for acute VTE (eg, with 
LMWH or an oral VKA) or have completed the treatment period 
in an open- label study comparing the efficacy and safety of da-
bigatran etexilate versus standard of care in children with acute 
VTE (study NCT01895777), although those who switched from 
dabigatran etexilate to standard of care during the latter study will 
be excluded.
Recruitment will be phased according to age group; adolescents 
aged 12 to <18 years will be recruited first and, based on ongoing 
evaluation of study data and data from other ongoing dabigatran 
etexilate pediatric studies by the DMC, recruitment will be opened 
to children aged 2 to <12 years. Based on consideration of these 
data, the DMC will recommend if and when it is appropriate to open 
recruitment to 0 to <2- year- old study participants.
3.4 | Study intervention
After written consent has been obtained, and if the patients meet 
all inclusion criteria and none of the exclusion criteria, they will initi-
ate dabigatran etexilate treatment or continue treatment if already 
receiving the drug as part of a prior study. Where patients have been 
receiving treatment with LMWH or oral VKAs, guidance will be pro-
vided to investigators on how to manage switching to dabigatran 
etexilate. Patients will be assigned twice- daily dabigatran etex-
ilate as capsules if they are able to swallow them (eg, patients aged 
≥8 years); otherwise the drug will be administered as pellets sprin-
kled on food (eg, ages 6 months to, in general, <8 years, but also al-
lowed up to 12 years), or as an oral liquid formulation (eg, from birth 
to, in general, age <6 months, but also allowed up to 12 months).
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The starting dose for each participant will be determined based 
on individual body weight and age using a specially developed no-
mogram, with the aim of attaining a target steady- state plasma 
concentration of dabigatran comparable with the observed plasma 
dabigatran concentration in adult VTE patients.20,36 As dabigatran 
is predominantly (approximately 80%) renally excreted,27,28 and 
its PK/PD relationship in children appears to be similar to that in 
adults,33,34 the doses in the nomogram were estimated using a 
scaling method developed by Hayton et al.29 that is considered ap-
plicable for drugs that are predominantly renally excreted. Using 
this method, the dose for an adult reference subject is scaled 
down according to a child’s expected maturation of renal function, 
which is defined based on age and weight assuming that there is no 
renal impairment.29 Dosing based on the Hayton formula results 
in a more individualized dosing algorithm in children. During the 
study, the suitability of the dosage determined for each patient 
will be confirmed by measuring steady- state trough plasma con-
centrations of dabigatran by high- pressure liquid chromatogra-
phy–tandem- mass spectrometry (HPLC- MS/MS), dTT (calibrated 
for determining dabigatran plasma concentrations), or an alterna-
tive registered assay. Concentrations will be measured as the pre-
dose steady- state plasma concentration (Cpre,ss) in samples from 
visits 3- 11 (Table 2), 10- 16 h after the previous dose. The first 
opportunity to evaluate and adjust dosage will therefore be after 
six consecutive doses have been taken, during the first week of 
treatment. If necessary, the dose will be adjusted. If the dabigatran 
concentration is not within the required range after one dose ad-
justment, the patient will be withdrawn from study treatment. The 
dosing regimen will be reviewed on an ongoing basis by the DMC 
and may be revised during the study as PK, safety, and efficacy 
data are obtained.
3.5 | Outcome measures
All efficacy criteria in this study are considered safety- related.
3.6 | Primary outcomes
The primary study outcomes are shown in Table 4. For the VTE 
outcome, all new or recurrent suspected episodes will be evalu-
ated using appropriate imaging modalities following local guidelines 
or as deemed necessary by the investigator and classified accord-
ing to the recommendations for perinatal and pediatric patients of 
the International Society on Thrombosis and Haemostasis (ISTH).13 
These recommendations will also be used to classify bleeding events 
as major bleeding, minor bleeding, or clinically relevant non-major 
bleeding.
3.7 | Secondary outcomes
Secondary outcomes are shown in Table 4. PTS will be evaluated 
using the modified Villalta score, one of the two pediatric PTS scores 
F IGURE  1 Trial administrative and oversight structure. The figure shows the organization and relationships of the roles and committees 
involved in the administration, oversight of the trial, and the trial sponsor. CRO, contract research organization; DMC, data monitoring 
committee; OPU, local Boehringer Ingelheim operating unit; SOP, standard operating procedure; TCM, trial clinical monitor; TMM, team 
member medicine. *Local laboratories may be employed after consultation with the sponsor to evaluate some assays, such as diluted 
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recognized by the ISTH.10,37 For the PK evaluations, dabigatran ex-
posure will be evaluated by HPLC- MS/MS as Cpre,ss at visit 3 and/or 
at future visits if required.
3.8 | Additional outcomes
Compliance will be calculated as a percentage from the actual 
number of dabigatran etexilate doses taken since the last count 
versus the number of dabigatran etexilate doses that should have 
been taken in the same period, based on the amounts of medica-
tion returned and verbal report. Parents or guardians will be re-
quested to bring all remaining trial medication to every clinic visit. 
Empty capsule containers, pellets boxes, or solution vials will also 
be requested for compliance evaluations and disposal. Parents or 
guardians will be requested to document failed or missed medica-
tion intake and provide information at the next study visit, and also 
to inform the investigator immediately if two or more consecutive 
doses are missed.
3.9 | Adverse event reporting
All AEs during the study will be recorded as on- treatment AEs, as 
will any that occur during the residual effect period for dabigatran 
(defined as 3 days after the last dose). Events will not have to have 
a causal relationship with treatment to be considered on- treatment 
AEs. Hepatic toxicity, defined as elevations of aspartate transami-
nase and or alanine transaminase ≥3 times the upper limit of normal 
(ULN) combined with elevated total bilirubin ≥2 ×  ULN found in the 
same blood sample, or renal dysfunction defined as an increase in 
creatinine of ≥2- fold from baseline to above the ULN, are considered 
AEs of special interest in this study. These events, and also serious 
AEs and non- serious AEs relevant to a serious AE, must be reported 
to the sponsor within 24 h.
3.10 | Determination of sample size
As discussed and agreed with the European Medicines Agency’s 
Paediatric Committee, a sample size of 100 patients is consid-
ered adequate to capture any safety signal for the primary safety 
endpoints defined in the study (at least one recurrent VTE, major 
bleed, or thromboembolic event–related death during the 12- 
month study), with 99% probability if the true composite event 
rate is 5%, or with 63% probability if the true event rate is 1%. 
Although the follow- up periods of the various studies of VTE 
recurrence have varied from several months to several years,6,8 
based on these results, such predicted event rates during the 12- 
month study period are realistic. However, should the proposed 
sample size of 100 patients prove to be insufficient and the DMC 
decides that additional safety data are required, recruitment will 
be kept open beyond 100 patients.
TABLE  3 Summary of key inclusion and exclusion criteria for the study
Inclusion criteria Exclusion criteria
● Males or females aged 0 to <18 years at time of informed consent/assent
● Previously documented objective diagnosis of VTE (eg, DVT, PE, central 
line thrombosis, sinus vein thrombosis), initially treated for ≥3 months (if 
treated with oral VKA at an intended INR of 2.0-3.0) or
● Completed the treatment period in an open-label study comparing the 
efficacy and safety of dabigatran etexilate vs. standard-of-care in pediatric 
patients VTE (NCT01895777)a and who also require continuation of 
anticoagulation for secondary prevention of VTE
● Have an unresolved clinical risk factor for VTE that requires further 
anticoagulation for secondary prevention
Risk factors include having a central venous line, presence of underlying 
disease (eg, cancer), antiphospholipid antibodies, systemic lupus 
erythematosus, diagnosis of thrombophilia
● Conditions associated with an increased risk of bleeding
● Renal dysfunction (eGFR <80 mL/min/1.73m2 using the 
Schwartz formula) or requirement for dialysis
● Active infective endocarditis
● Heart valve prosthesis requiring anticoagulation
● Hepatic disease (including active liver disease [eg, hepatitis 
A, B, or C], or persistent ALT/AST/AP >3 X ULN within 
3 months of screening)
● Pregnant or breast-feeding females
● Females who have reached menarche and are not using an 
acceptable method of birth control, or who do not plan to 
continue using this method throughout the study and/or do 
not agree to adhere to pregnancy testing required by the 
protocol
● Patients in age group 0 to <2 years with gestational age at 
birth <37 weeks or with body weight lower than the third 
percentile (according to the WHO child growth standards)
● Anemia (hemoglobin <80 g/l) or thrombocytopenia 
(platelet count <80 × 109/l) at screening. Transfusions 
during the screening period are allowed, provided a 
satisfactory hemoglobin or platelet level is attained  
prior to visit 2
● Allergy or sensitivity to any component of the study 
medication or its solvent
ALT, alanine aminotransferase; AP, alkaline phosphatase; AST, aspartate transaminase; DVT, deep vein thrombosis; eGFR, estimated glomerular filtra-
tion rate; INR, international normalized ratio; PE, pulmonary embolism; ULN, upper limit of normal; VKA, vitamin K antagonist; VTE, venous thrombo-
embolism; WHO, World Health Organization.
aExcept for those who switched from dabigatran etexilate to standard care during this study.
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3.11 | Data and statistical analysis
Findings for the primary outcomes and for the secondary PTS 
outcome will be presented as time- to- event values and summa-
rized as Kaplan–Meier estimates with rates of occurrence at 6 and 
12 months; descriptive rates for each outcome will also be calcu-
lated. Subgroups may be explored when appropriate, including but 
not limited to age groups, and type and duration of standard of care 
treatment at study entry. Patients with early withdrawal or lost to 
follow- up will be deemed non- events for the descriptive analyses; 
patients who withdraw early or who are lost to follow- up, as well as 
those who do not have VTE or bleeding episodes, will be censored 
from the survival analyses.
PK results will be summarized descriptively and compared with 
exposure data from previous studies in adult patients and healthy 
volunteers. Data on dose adjustments during the treatment period 
will be summarized descriptively. The PD findings will be evaluated 
using descriptive statistics and ratios to baseline (ie, visit 2), also 
determined to explore the dose- coagulation response relationship 
in this pediatric population. PK and PD and PK/PD relationships will 
be further explored using graphical analyses. All patients with ≥1 
post- baseline measurement will be included in the PK/PD full analy-
sis set. Descriptive statistics will be utilized for overall assessments 
of safety and AEs.
4  | DISCUSSION
This study has been designed (as agreed with the European 
Medicines Agency’s Paediatric Committee) to evaluate the safety 
of extended anticoagulant therapy with dabigatran etexilate 
for the secondary prevention of VTE in ≥100 children aged 0 to 
<18 years. An open- label design will enable ongoing DMC review 
of outcomes within this study, as well as of other related studies. 
This will not only ensure the safety of participating patients but 
will also enable modification of the study design and decisions on 
the inclusion of the 0 to <2- year- old age group and, if emerging 
data warrant, recruitment of additional participants. The single- 
arm design and patient sample size are considered appropriate for 
a safety study such as this. However, the study should be consid-
ered as part of the wider pediatric dabigatran development pro-
gram, which includes the phase III study NCT01895777, which is 
to provide efficacy and safety data for dabigatran compared with 
standard- of- care for the acute treatment of VTE in 180 patients. 
Although the two trial populations differ (acute and secondary 
VTE) they are considered to be similar enough to allow bleeding 
outcome data from the comparator arm of study NCT01895777 
to be compared to bleeding outcomes in the current study. When 
considered as a study program, the two studies combined will pro-
vide VTE data for over 280 patients.
The additional central adjudication of VTE and bleeding events 
by an independent panel will allow for accurate and consistent clas-
sification of events, which should enable comparison with data from 
other sites and other studies. Use of recognized pediatric- specific 
VTE and bleeding- event classification criteria13 and of a pediatric 
PTS scoring system10,37,38 will also aid such comparisons.
Orally administered dabigatran etexilate may overcome some of 
the compliance- related challenges presented by currently available 
treatments; for example, LMWH requires subcutaneous injection,1 
and the physiologically age- appropriate lower circulating levels of 
antithrombin (eg, in newborns and infants aged ≤6 months or due 
to underlying disease),1,6,24 may affect its activity in some patients. 
Dosing according to the nomogram has led to comparable exposure 
between pediatric and adult VTE patients and, in addition, the PK/
PD relationship is found to be similar between these two patient 
populations in phase 2a studies.33,34 Routine coagulation monitor-
ing is not required during its use for the treatment and secondary 
prevention of VTE in adults.16–20 The available PK and PD data from 
this study along with study NCT01895777 will be used to refine the 
nomogram procedure for determining pediatric dabigatran etexilate 
dosages. Data on compliance, as well as the availability of different 
TABLE  4 Study primary and secondary endpoints
Primary endpoints
• Recurrence of VTE at 6 and 12 months, defined as13: 
o All recurrent VTE, as either contiguous progression or 
non-contiguous new thrombus including DVT, PE, paradoxical 
embolism
• Mortality overall and related to thrombotic or thromboembolic 
events at 6 and 12 months
• Major and minor (including clinically non-relevant bleeding 
events) at 6 and 12 months, defined as13: 
o Major bleeding 
▪ Fatal bleeding
▪ Clinically overt bleeding associated with a decrease in 
hemoglobin of ≥2 g/dl (20 g/l) in a 24-hour period
▪ Bleeding that is retroperitoneal, pulmonary, intracranial, or 
otherwise involves the central nervous system
▪ Bleeding that requires surgical intervention in an operating 
suite
o Clinically relevant non-major bleeding 
▪ Overt bleeding for which a blood product is administered 
and that is not directly attributable to the patient’s 
underlying medical condition
▪ Bleeding that requires medical or surgical intervention to 
restore hemostasis, other than in an operating suite
o Minor bleeding
▪ Any overt or macroscopic evidence of bleeding that does 
not fulfil the criteria for either major bleeding or clinically 
relevant, non-major bleeding
• Overall mortality and thrombotic or thromboembolism-related 
mortality 
Secondary endpoints
• Occurrence of post-thrombotic syndrome at 6 and 12 months
• PD evaluations (ie, aPTT and ECT) at visit 4
• Number of dabigatran etexilate dose adjustments required during 
the treatment period
aPTT, activated partial thromboplastin time; DVT, deep vein thrombosis; 
ECT, ecarin clotting time; PD, pharmacodynamics; PE, pulmonary embo-
lism; VTE, venous thromboembolism.
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types of oral formulations, will provide further information on the 
suitability of dabigatran etexilate for pediatric use and also aid for-
mulation selection.
Estimates of the risks of VTE recurrence after an initial event in 
children vary8,9; however, in children, as in adults, recurrence is asso-
ciated with increased morbidity and mortality,1,2,6,7 hence extended 
anticoagulant therapy may be warranted until VTE risk factors are 
resolved.1 Further, although estimates of rates of PTS in children 
vary considerably,7,9–11 it has been found to be associated with in-
creased morbidity and cost.39 There have been far fewer studies on 
the natural history, treatment, and secondary prevention of VTE in 
children than in adults.1,9,40 Collaborative efforts between industry 
and academia, as in this study, are needed to enable the implemen-
tation of well- designed, adequately powered trials that can address 
this lack of data and investigate potentially advantageous new anti-
coagulant options. Although this study is focused on the safety of 
dabigatran etexilate, additional data will be collected to evaluate the 
rates of VTE recurrence in children with persisting risk factors for 
VTE, on anticoagulant- related bleeding risk, and on PTS after an ini-
tial VTE episode.
The in vitro and clinical investigation plan for dabigatran etex-
ilate in children is in agreement with ISTH SCC recommendations 
regarding the key components of a pediatric investigation plan for 
an anticoagulant drug.41 As per the ISTH recommendations, the 
evaluation of dabigatran in pediatric patients has followed a step-
wise approach, beginning with adolescents and then proceeding to 
younger age groups. In addition, previous dabigatran studies have 
confirmed that the PK- PD relationship in children is comparable with 
that seen in adults.32,33 The design of the phase 3 study we describe 
in this paper takes into consideration the efficacy and safety data 
of dabigatran in adults with VTE (due to the difficulties of conduct-
ing a fully powered study in children) and will also continue to as-
sess PK and PD parameters, as per the ISTH recommendations for 
pediatric VTE clinical studies.41 In addition, the study will evaluate 
age- appropriate formulations of dabigatran (pellets and an oral liq-
uid formulation), the importance of which is highlighted in the ISTH 
recommendations.41
5  | STUDY LIMITATIONS
This study has some design limitations that affect extrapolation of 
its findings beyond the predetermined safety objectives. As the 
overriding objective of this study is to evaluate the safety of dabi-
gatran etexilate, the design does not include a comparator arm or 
efficacy endpoints. However, this study will provide safety data that 
will be complementary to those obtained from study NCT01895777, 
which does contain a standard- of- care comparator arm. Additionally, 
regulatory guidance notes that findings on efficacy can be extrapo-
lated from adults to children if the effects of a drug and the course 
of a disease are similar in both populations.31 Finally, the duration 
of treatment in this study will be 12 months, which may not be long 
enough to identify certain long- term complications (eg, osteoporosis) 
that have been reported with long- term oral VKA use in pediatric pa-
tients,1,42 or to provide more information on PTS, which can also be 
a longer- term complication of VTE.1 With regard to PTS, it is also im-
portant to note that some patients recruited into this study will have 
been treated for the previous 3 months with dabigatran for their first 
episode of VTE and some with standard care.
6  | CONCLUSIONS
This study is designed to provide data on the safety of dabigatran 
etexilate for the secondary prevention of VTE in children aged 0 
to 18 years during up to 12 months of treatment. It will provide in-
formation to further guide dabigatran dosing for pediatric patients 
and about treatment compliance and choice of formulations for this 
population. Further data on the natural history of VTE recurrence in 
children and the risk of consequences such as PTS will also become 
available as a result of this study.
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